OraSure Technologies — Third Quarter 2026 Earnings Summary

OraSure Technologies reported third-quarter 2026 total net revenues of $30.9 million, representing a 14% year-over-year increase driven by growth in its core business. The company achieved a GAAP gross margin of 45.2%, an improvement of over 170 basis points compared to the prior year, while reporting a GAAP net loss of $13.1 million. Strategic product launches, including the Colli-Pee Dx Urine Collection Kit and OraQuick Ebola 2.0 Rapid Antigen Test, generated initial orders during the quarter. Looking ahead, OraSure expects an acceleration of year-over-year revenue growth in 2027 and provided a fourth-quarter revenue guidance range of $30.0 million to $32.0 million.